REN-1654 in post-herpetic neuralgia: a multi-center, placebo controlled, 3-week dose-finding study, with a 3-week active-treatment extension.
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2017
At a glance
- Drugs REN 1654 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- 21 Oct 2005 New trial record.